Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarabia De Ardanaz, Luis, Andreu-Ubero, Jose M., Navidad-Fuentes, Miriam, Ferrer-González, Miguel Ángel, Ruíz del Valle, Victor, Salcedo-Bellido, Inmaculada, Barrios-Rodríguez, Rocío, Cáliz-Cáliz, Rafael, Requena, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281134/
https://www.ncbi.nlm.nih.gov/pubmed/34276355
http://dx.doi.org/10.3389/fphar.2021.620187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281134/
https://www.ncbi.nlm.nih.gov/pubmed/34276355
http://dx.doi.org/10.3389/fphar.2021.620187

Ejemplares similares